{"id":"da-001","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DA-001 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. Additionally, DA-001 has been shown to have anti-angiogenic properties, further contributing to its anti-tumor effects.","oneSentence":"DA-001 is a small molecule that targets the PI3K/AKT pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:49.877Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06648850","phase":"PHASE2, PHASE3","title":"Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth","status":"NOT_YET_RECRUITING","sponsor":"Applied Biology, Inc.","startDate":"2026-02-16","conditions":"Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia","enrollment":800},{"nctId":"NCT06778265","phase":"PHASE1","title":"An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai UniXell Biotechnology Co., Ltd","startDate":"2025-03-01","conditions":"Parkinson Disease, Idiopathic","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DA-001","genericName":"DA-001","companyName":"Applied Biology, Inc.","companyId":"applied-biology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DA-001 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic breast cancer, Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}